The physical and toxicological attributes associated with the substance haven’t been identified. The product was created for research and forensic purposes.
AB-FUBINACA is an indazole-based synthetic cannabinoid (CB) with 10-fold higher affinity relating to the main CB1 receptor (Ki = 0.9 nM) in contrast to JWH 018 .
AB-FUBINACA was initially synthesized by Pfizer, Inc. as an effective powerful CB1 receptor modulator for possible therapeutic usage, however not too long ago had been discovered together with AB-PINACA in prohibited herbal products.
AB-CHMINACA is structurally relevant to AB-FUBINACA which includes a cyclohexyl group replaced for the 4-fluorophenyl group.
There are no reviews yet.